Literature DB >> 1717171

Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells.

D A Cheresh1.   

Abstract

Human melanoma represents one of the most metastatic cancers in man. The capacity of melanoma cells to invade a variety of tissues and extracellular matrices is, in part, due to their repertoire of adhesion receptors. To this end, human melanoma cells express multiple integrin cell adhesion receptors among these is the vitronectin receptor, alpha v beta 3. This adhesion receptor enables melanoma cells to attach to a wide variety of extracellular matrix components containing the sequence Arg-Gly-Asp. This review will focus on the biosynthetic, biochemical and biological properties of this receptor expressed on the surface of human melanoma cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717171     DOI: 10.1007/bf00046839

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  42 in total

1.  Arg-Gly-Asp recognition by a cell adhesion receptor requires its 130-kDa alpha subunit.

Authors:  D A Cheresh; J R Harper
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

2.  Involvement of gangliosides and glycoprotein fibronectin receptors in cellular adhesion to fibronectin.

Authors:  W B Stallcup
Journal:  Exp Cell Res       Date:  1988-07       Impact factor: 3.905

3.  The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit.

Authors:  J W Smith; D A Cheresh
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

4.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.

Authors:  S M Albelda; S A Mette; D E Elder; R Stewart; L Damjanovich; M Herlyn; C A Buck
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

5.  Osteopontin--a possible anchor of osteoclasts to bone.

Authors:  F P Reinholt; K Hultenby; A Oldberg; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells.

Authors:  M J Humphries; K Olden; K M Yamada
Journal:  Science       Date:  1986-07-25       Impact factor: 47.728

7.  Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites.

Authors:  J W Smith; Z M Ruggeri; T J Kunicki; D A Cheresh
Journal:  J Biol Chem       Date:  1990-07-25       Impact factor: 5.157

8.  Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin.

Authors:  D A Cheresh; F G Klier
Journal:  J Cell Biol       Date:  1986-05       Impact factor: 10.539

9.  Cloning, primary structure and properties of a novel human integrin beta subunit.

Authors:  H Ramaswamy; M E Hemler
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

10.  Cell surface distribution of fibronectin and vitronectin receptors depends on substrate composition and extracellular matrix accumulation.

Authors:  I I Singer; S Scott; D W Kawka; D M Kazazis; J Gailit; E Ruoslahti
Journal:  J Cell Biol       Date:  1988-06       Impact factor: 10.539

View more
  16 in total

1.  Role of integrin alpha(v)beta3 in the early phase of liver metastasis: PET and IVM analyses.

Authors:  Hironori Kikkawa; Masako Kaihou; Natsuko Horaguchi; Takayuki Uchida; Hidetoshi Imafuku; Ayano Takiguchi; Yukako Yamazaki; Chieko Koike; Ryoko Kuruto; Takeharu Kakiuchi; Hideo Tsukada; Yoshikazu Takada; Nariaki Matsuura; Naoto Oku
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 2.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

3.  Pharmacoproteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis.

Authors:  Ji-Young Bang; Eung-Yoon Kim; Dong-Ku Kang; Soo-Ik Chang; Moon-Hi Han; Kwang-Hyun Baek; In-Cheol Kang
Journal:  Mol Cell Proteomics       Date:  2011-05-10       Impact factor: 5.911

Review 4.  Recent advances in the treatment of malignant melanoma with gene therapy.

Authors:  E M Hersh; A T Stopeck
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

5.  The inhibition of vascular smooth muscle cell migration by peptide and antibody antagonists of the alphavbeta3 integrin complex is reversed by activated calcium/calmodulin- dependent protein kinase II.

Authors:  C Bilato; K A Curto; R E Monticone; R R Pauly; A J White; M T Crow
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

6.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

Authors:  C O Yun; K F Nolan; E J Beecham; R A Reisfeld; R P Junghans
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

Review 7.  Integrin and growth factor receptor alliance in angiogenesis.

Authors:  Payaningal R Somanath; Alieta Ciocea; Tatiana V Byzova
Journal:  Cell Biochem Biophys       Date:  2008-12-02       Impact factor: 2.194

8.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

9.  Integrin alphavbeta3 is expressed in selected microvessels after focal cerebral ischemia.

Authors:  Y Okada; B R Copeland; G F Hamann; J A Koziol; D A Cheresh; G J del Zoppo
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

10.  Inhibitory effects of adhesion oligopeptides on the invasion of squamous carcinoma cells with special reference to implication of alpha v integrins.

Authors:  E Kawahara; K Imai; S Kumagai; E Yamamoto; I Nakanishi
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.